- Home
- VINP vs EYPT Comparison
VINP vs EYPT Comparison
Compare VINP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | EYPT |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 312.1M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | VINP | EYPT |
|---|---|---|
| Price | $9.32 | $3.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $14.02 | ★ $25.91 |
| AVG Volume (30 Days) | 34.9K | ★ 3.1M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $17.76 | N/A |
| Revenue Next Year | $13.10 | $943.27 |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $3.27 |
| 52 Week High | $13.61 | $19.11 |
Technical Indicators
Market Signals| Indicator | VINP | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 29.43 |
| Support Level | $9.31 | N/A |
| Resistance Level | $10.17 | $14.72 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 31.03 | 2.27 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.